Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
Neuraxis, Inc. (symbol: NRXS) is a growth-stage company pioneering in the development of neuromodulation therapies aimed at treating chronic and debilitating conditions in children. With a steadfast focus on disorders of gut-brain interaction (DGBIs), the company is committed to improving the lives of pediatric and adolescent populations. Neuraxis leverages its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology to deliver targeted therapies that are both innovative and effective.
In recent months, Neuraxis has made significant strides. Following its IPO, the company has successfully built a robust portfolio of research publications, which has enabled it to secure broad insurance policy coverage sooner than anticipated. This has led to increased revenues in regions such as Massachusetts and Wisconsin, where written policy coverage is in place.
As the company moves into 2024, it continues to focus on expanding insurance policy coverage, with 10 major meetings scheduled in the first quarter alone. Additionally, Neuraxis is preparing for the FDA clearance of a new pediatric IB-Stim indication by the end of 2024 and the introduction of a new RED product aimed at the adult gastrointestinal market, both expected to generate substantial revenue growth.
Financially, Neuraxis recently filed a restatement of its third-quarter 2023 financial results, resulting in a $3.7 million increase to the company's net loss and additional paid-in capital. However, this restatement is unrelated to revenues or cash expenses, and the company's cash position remains unchanged.
Looking ahead, Neuraxis is well-positioned for continued success. The company's dedicated team remains focused on advancing policy coverage, expanding its product pipeline, and preparing markets and children’s hospitals for effective treatments once coverage is in place.
For more detailed updates and to stay informed on the latest developments, shareholders and interested parties are encouraged to participate in the company’s upcoming first-quarter 2024 financial results conference call. Details for accessing the live webcast and replay are available on the company's Investor Relations website.
NeurAxis, Inc. (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report summarized financial results for the quarter ended June 30, 2024, on Friday, August 9, 2024, before market open. A conference call is scheduled for the same day at 9:00 am ET to review the results.
Interested parties can access the call via a live webcast available on the company's Investor Relations website. Participants can also join through a call-in option by registering online. A webcast replay will be available after the call on the company's website for those unable to attend live.
NeurAxis announced a new submission to the FDA for expanding its IB-Stim label to include ages 8-21 and allow marketing of 4 devices per prescription. This expansion is backed by a systematic literature review showing the effectiveness of IB-Stim in a broader age range. Additionally, NeurAxis disclosed its compliance with NYSE guidelines regarding audit opinions, highlighting their current financial strategy, which includes securing $3.0 million and $3.1 million in convertible note financing and closing an additional $3.0 million in convertible notes to improve their financial position.
NeurAxis (NYSE American: NRXS) reported a 19.7% revenue decline to $646.6K for Q1 2024, compared to $805.1K in Q1 2023. The decline was due to fewer shipments to certain customers due to insurance reimbursement processing delays.
Despite the revenue drop, the company expanded its covered lives by 400%, reaching 22.5 million from 4.5 million previously. Key partnerships with BCBS in various regions contributed significantly to this growth.
The company announced positive clinical trial results for its IB-Stim™ device, showcasing significant improvements in pediatric patients with DGBIs.
NeurAxis secured $6.1 million in convertible note financing and expects FDA clearance for its new rectal expulsion device (RED) in Q4 2024, which is expected to contribute to revenue growth in 2H24.
However, the company reported a net loss of $2.1 million, a 2.4% improvement from Q1 2023, and an operating loss increase of 104.4% to $1.8 million. The company has $81.7K cash on hand and $1.4 million in short-term debt.
NeurAxis (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies for chronic and debilitating conditions, will be participating in the Lytham Partners Spring 2024 Investor Conference.
The virtual event will take place on May 30, 2024. The company will present a webcast at 9:30 a.m. ET, which can be accessed via the conference's homepage or directly on the webcast platform. The presentation will be available for replay after the event.
Additionally, NeurAxis's management will engage in virtual one-on-one meetings with investors throughout the conference. Interested parties can arrange these meetings through Lytham Partners by contacting them or registering on the conference website.
NeurAxis announced the expansion of medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) through a Blue Cross Blue Shield (BCBS) licensee in Florida. This new policy covers nearly six million members, increasing the total coverage for IB-Stim to approximately 22.5 million lives. IB-Stim™ is a non-surgical device FDA-cleared for treating functional abdominal pain linked to irritable bowel syndrome (IBS) in adolescents. The expansion aligns with NeurAxis' commercialization strategy and is expected to boost market adoption and revenue growth.
NeurAxis (NRXS), a medical technology company specializing in neuromodulation therapies for chronic conditions, will release its Q1 2024 financial results on May 22, 2024, before market open. The period covered is up to March 31, 2024. A conference call is scheduled for the same day at 9:00 am ET to review the results. NeurAxis has also filed a Form 12b-25, indicating a delay in filing its Form 10-Q, which is now expected to be filed on May 20, 2024.
The conference call can be accessed via a live webcast available in the Investor Relations section of NeurAxis' website, and replay options will be provided. Participants can submit questions through the webcast portal or by emailing NRXS@lythampartners.com.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
What is Neuraxis, Inc.?
What is PENFS technology?
What recent achievements has Neuraxis made?
What are Neuraxis' plans for 2024?
How has Neuraxis' financial condition changed recently?
How can I stay updated on Neuraxis' latest news?
What is the significance of Neuraxis' research publications?
What markets does Neuraxis serve?
How can I contact Neuraxis' Investor Relations?
When is Neuraxis' next financial results conference call?
